Douglas Ingram

Biotech

Sarepta's DMD gene therapy fails phase 2 motor function test

Functional motor ability scores in the SRP-9001 arm were statistically no better than in the placebo group, almost halving Sarepta’s stock price.

Nick Paul Taylor Jan 8, 2021 8:10am

Sarepta taps Codiak's exosome tech in $72.5M neuromuscular deal

Jun 23, 2020 10:00am

Wheelchair

Sarepta CEO dispels FDA 'bias' theory

Nov 8, 2019 8:12am

DNA genomics precision medicine

Sarepta sees muscle gains with DMD gene therapy

Oct 4, 2018 11:00am

DNA

Sarepta boosts gene therapy with $30M Lacerta deal

Aug 9, 2018 10:39am

Wheelchair

Sarepta adds to gene therapy pipeline via Myonexus pact

May 4, 2018 9:08am